Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model

Harada,Suguru; Yanagisawa,Mieko; Kaneko,Saori; Yorozu,Keigo; Yamamoto,Kaname; Moriya,Yoichiro; Harada,Naoki

doi:10.3892/mco.2015.609

Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model

Authors:
- Suguru Harada
- Mieko Yanagisawa
- Saori Kaneko
- Keigo Yorozu
- Kaname Yamamoto
- Yoichiro Moriya
- Naoki Harada
View Affiliations

Affiliations: Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa 247‑8530, Japan
Published online on: July 21, 2015 https://doi.org/10.3892/mco.2015.609
Pages: 987-994
Copyright: © Harada et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU) plus cisplatin, significantly increased overall survival compared with chemotherapy alone (ToGA trial). In addition, adjuvant therapy with capecitabine plus oxaliplatin (XELOX) improved the survival of patients who received curative D2 gastrectomy (CLASSIC trial). However, the efficacy of the combination of trastuzumab with XELOX for patients with HER2‑positive gastric cancer remains unknown. The aim of this study, was to investigate the efficacy of the combination of trastuzumab with XELOX in a HER2‑positive human gastric cancer xenograft model. Combination treatment with these three agents (trastuzumab 20 mg/kg, capecitabine 359 mg/kg and oxaliplatin 10 mg/kg), was found to exhibit a significantly stronger antitumor activity in NCI‑N87 xenografts compared with either trastuzumab or XELOX alone. In this model, treatment with trastuzumab alone or trastuzumab plus oxaliplatin enhanced the expression of thymidine phosphorylase (TP), a key enzyme in the generation of 5‑FU from capecitabine in tumor tissues. In in vitro experiments, trastuzumab induced TP mRNA expression in NCI‑N87 cells. In addition, NCI‑N87 cells co‑cultured with the natural killer (NK) cell line CD16(158V)/NK‑92 exhibited increased expression of TP mRNA. When NCI‑N87 cells were cultured with CD16(158V)/NK‑92 cells in the presence of trastuzumab, the mRNA expression of cytokines reported to have the ability to induce TP was upregulated in tumor cells. Furthermore, a medium conditioned by CD16(158V)/NK‑92 cells also upregulated the expression of TP mRNA in NCI‑N87 cells. These results suggest that trastuzumab promotes TP expression, either by acting directly on NCI‑N87 cells, or indirectly via a mechanism that includes trastuzumab‑mediated interactions between NK and NCI-N87 cells. Therefore, the combination of trastuzumab with XELOX may be a potent therapy for HER2-positive gastric cancer.

View Figures

View References

1	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar : PubMed/NCBI
2	Sasako M, Saka M, Fukagawa T, Katai H and Sano T: Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg. 24:101–107. 2007. View Article : Google Scholar : PubMed/NCBI
3	Cunningham D, Allum WH, Stenning SP, et al: MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
4	Cunningham D, Starling N, Rao S, et al: Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
5	Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:725–730. 2001. View Article : Google Scholar : PubMed/NCBI
6	Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
7	García I, Vizoso F, Martín A, et al: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 10:234–241. 2003. View Article : Google Scholar : PubMed/NCBI
8	Tanner M, Hollmen M, Junttila TT, et al: Amplification of HER 2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278. 2005. View Article : Google Scholar : PubMed/NCBI
9	Molina MA, Codony-Servat J, Albanell J, et al: Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:4744–4749. 2001.PubMed/NCBI
10	Izumi Y, Xu L, di Tomaso E, Fukumura D and Jain RK: Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature. 416:279–280. 2002. View Article : Google Scholar : PubMed/NCBI
11	Barok M, Isola J, Pályi-Krekk Z, et al: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 6:2065–2072. 2007. View Article : Google Scholar : PubMed/NCBI
12	Valabrega G, Montemurro F and Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 18:977–984. 2007. View Article : Google Scholar : PubMed/NCBI
13	Musolino A, Naldi N, Bortesi B, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 26:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI
14	Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 13:228–233. 2007. View Article : Google Scholar : PubMed/NCBI
15	Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
16	Smith I, Procter M, Gelber RD, et al: HERA study team: Two year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 369:29–36. 2007. View Article : Google Scholar : PubMed/NCBI
17	Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K and Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 59:795–805. 2007. View Article : Google Scholar : PubMed/NCBI
18	Bang YJ, Van Cutsem E, Feyereislova A, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ishikawa T, Utoh M, Sawada N, et al: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 55:1091–1097. 1998. View Article : Google Scholar : PubMed/NCBI
20	Pentheroudakis G and Twelves C: The rational development of capecitabine from the laboratory to the clinic. Anticancer Res. 22:3589–3596. 2002.PubMed/NCBI
21	Schüller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmaco. 45:291–297. 2000. View Article : Google Scholar
22	Ishikawa T, Sekiguchi F, Fukase Y, Sawada N and Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 58:685–690. 1998.PubMed/NCBI
23	Yasuno H, Kurasawa M, Yanagisawa M, Sato Y, Harada N and Mori K: Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes. Oncol Rep. 29:451–458. 2013.PubMed/NCBI
24	Ishii R, Takiguchi N, Oda K, Koda K and Miyazaki M: Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer. Int J Oncol. 19:717–722. 2001.PubMed/NCBI
25	Nishimura G, Terada I, Kobayashi T, et al: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep. 9:479–482. 2002.PubMed/NCBI
26	Terashima M, Fujiwara H, Takagane A, et al: Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer. 38:2375–2381. 2002. View Article : Google Scholar : PubMed/NCBI
27	Endo M, Shinbori N, Fukase Y, et al: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer. 83:127–134. 1999. View Article : Google Scholar : PubMed/NCBI
28	Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 4:1013–1019. 1998.PubMed/NCBI
29	Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y and Ishitsuka H: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 5:2948–2953. 1999.PubMed/NCBI
30	Sawada N, Kondoh K and Mori K: Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. Oncol Rep. 18:775–778. 2007.PubMed/NCBI
31	Ouchi KF, Yanagisawa M, Sekiguchi F and Tanaka Y: Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol. 57:693–702. 2006. View Article : Google Scholar : PubMed/NCBI
32	Woynarowski JM, Faivre S, Herzig MC, et al: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol. 58:920–927. 2000.PubMed/NCBI
33	Dong N, Jiang W, Li H, Liu Z, Xu X and Wang M: Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am J Clin Oncol. 32:559–563. 2009. View Article : Google Scholar : PubMed/NCBI
34	Liu C, Sun Q, Hang X, Zhong B and Wang D: Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anticancer Drugs. 19:825–831. 2008. View Article : Google Scholar : PubMed/NCBI
35	Park YH, Lee JL, Ryoo BY, et al: Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol. 61:623–629. 2008. View Article : Google Scholar : PubMed/NCBI
36	Bang YJ, Kim YW, Yang HK, et al: CLASSIC trial investigators: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
37	Yamashita Kashima Y, Iijima S, Yorozu K, et al: Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res. 17:5060–5070. 2011. View Article : Google Scholar : PubMed/NCBI
38	Mori K, Hasegawa M, Nishida M, et al: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol. 17:33–38. 2000.PubMed/NCBI
39	Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T and Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull. 19:1407–1411. 1996. View Article : Google Scholar : PubMed/NCBI
40	Spector NL and Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 27:5838–5847. 2009. View Article : Google Scholar : PubMed/NCBI
41	Kute TE, Savage L, Stehle JR Jr, et al: Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother. 58:1887–1896. 2009. View Article : Google Scholar : PubMed/NCBI
42	Arnould L, Gelly M, Penault-Llorca F, et al: Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 94:259–267. 2006. View Article : Google Scholar : PubMed/NCBI
43	Varchetta S, Gibelli N, Oliviero B, et al: Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67:11991–11999. 2007. View Article : Google Scholar : PubMed/NCBI
44	Akiyama S, Furukawa T, Sumizawa T, et al: The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci. 95:851–857. 2004. View Article : Google Scholar : PubMed/NCBI
45	Albanell J, Codony J, Rovira A, Mellado B and Gascón P: Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 532:253–268. 2003. View Article : Google Scholar : PubMed/NCBI